Received Sep 2, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| COVID19 | COVID19 (COVID19 (PFIZER-BIONTECH)) | PFIZER\BIONTECH | 7+ | ME6072 | IM / LA |
| COVID19 | COVID19 (COVID19 (PFIZER-BIONTECH)) | PFIZER\BIONTECH | 1 | ME6072 | LA |
stroke; This is a spontaneous report received from a Consumer or other non HCP. A 72-year-old female patient (not pregnant) received BNT162b2 omicron (kp.2) (COMIRNATY (2024-2025 FORMULA)), on 14Aug2025 at 16:00 as dose 1, single (Lot number: ME6072) at the age of 72 years, in left deltoid for covid-19 immunisation. The patient's relevant medical history included: "Leukemia", start date: 2012 (unspecified if ongoing); "Melanoma", start date: 2020 (unspecified if ongoing); "Known allergies: Pineapple" (unspecified if ongoing). Concomitant medication(s) included: WELLBUTRIN, start date: 31Mar2025. The following information was reported: CEREBROVASCULAR ACCIDENT (hospitalization, medically significant) with onset 15Aug2025 at 03:00, outcome "recovering", described as "stroke". The patient was hospitalized for cerebrovascular accident (start date: 2025, discharge date: 2025, hospitalization duration: 1 day(s)). Therapeutic measures were taken as a result of cerebrovascular accident. Clinical course: AE treatment included Observation and Medications. The patient did not receive any other vaccine on same date or in four weeks.
Medical History/Concurrent Conditions: Fruit allergy; Leukemia; Melanoma
WELLBUTRIN